Sign inJoin waitlistJoin the waitlist

Angela Alistar

Medical Director, GI Medical Oncology Medical Director, Phase I Breakthrough Treatment Center · Rutgers Health

Credentials: · · · ·

History

GI Medical Oncology Medical Director · Rutgers Health
Present

Mount Sinai Hospital
2004–2006
Englewood Hospital Medical Center
2001–2004
University of Medicine and Pharmacy, Cluj Napoca, Romania
1997–2001

Research

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein
Immunity · 2020 · 275 citations
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label,…
The Lancet Oncology · 2017 · First of 25 authors · Corresponding · 193 citations
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Cancer Immunology Research · 2016 · 88 citations

Tim Pardee
4 papers
William Petty
4 papers
Boris Pasche
3 papers
Erkut Borazanci
3 papers
RB
Rhonda Bitting
3 papers
RD
Rodwige Desnoyers
3 papers
Stefan Grant
3 papers
Alexandra Thomas
2 papers
Anup Kasi
2 papers
AB
Arthur Blackstock
2 papers
AM
Autumn McRee
2 papers
Barry DeYoung
2 papers

Clinical trials

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Principal investigator · Completed · Phase 1
Sirnaomics
2021–2024
A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer
Principal investigator · Unknown · Phase 1
Atlantic Health System
2017–2019
Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery
Principal investigator · Terminated
Wake Forest University Health Sciences
2015–2017
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Site PI · Recruiting · Phase 2
Tiago Biachi de Castria
2025–2028